Receptor News and Research

RSS

Are genes and hormones determinants of empathy and sensitivity in human nature?

According to latest research a first look or observation for just about 20 seconds maybe all that is needed to know if a person is nurturing and socially sensitive. These people may be genetically wired to be so say researchers.

17 Nov 2011

Researchers discover a factor in synapse-building and pruning

Like a gardener who stakes some plants and weeds out others, the brain is constantly building networks of synapses, while pruning out redundant or unneeded synapses. Researchers at The Jackson Laboratory led by Assistant Professor Zhong-wei Zhang, Ph.D., have discovered a factor in synapse-building, also showing that the building and pruning processes occur independent of each other.

17 Nov 2011

Male breast cancer patients report tamoxifen side effects

About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which prompts more than 20 percent of them to discontinue treatment, according to researchers at The University of Texas MD Anderson Cancer Center.

17 Nov 2011

Just 20 seconds to know whether a stranger is trustworthy, kind or compassionate

There's definitely something to be said for first impressions. New research from the University of California, Berkeley, suggests it can take just 20 seconds to detect whether a stranger is genetically inclined to being trustworthy, kind or compassionate.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

International consortium develops first-in-class adiponectin receptor agonist

A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium lead by Dr. Eva Surmacz, Associate Professor in Biology (Adjunct) and director of the Obesity and Cancer Program at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology.

16 Nov 2011

New computer chip models how neurons communicate with each other at synapses

For decades, scientists have dreamed of building computer systems that could replicate the human brain's talent for learning new tasks. MIT researchers have now taken a major step toward that goal by designing a computer chip that mimics how the brain's neurons adapt in response to new information. This phenomenon, known as plasticity, is believed to underlie many brain functions, including learning and memory.

16 Nov 2011

Specific gene variant may increase risk of premature death in people with alcohol dependency

People who are alcohol-dependent and who also carry a particular variant of a gene run an increased risk of premature death. This is a recent finding from the interdisciplinary research at the Department of Psychology and the Sahlgrenska Academy at the University of Gothenburg, Sweden.

15 Nov 2011

Eliminating drug co-pays improves medication adherence in heart attack patients

The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from Brigham and Women's Hospital (BWH) evaluated whether eliminating co-payments for these medications would increase adherence and improve outcomes in patients who have had a heart attack.

15 Nov 2011

Cortex third quarter net loss increases to $1,175,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $1,175,000, or $0.01 per share, for the quarter ended September 30, 2011, compared with a net loss of approximately $528,000, or $0.01 per share, for the corresponding prior year quarter.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Scientists suppress NCoR1 protein and create mighty mice

A team of researchers at EPFL, the University of Lausanne and the Salk Institute created super strong, marathon mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach.

11 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

Researchers from the Wellcome Trust Sanger Institute in the U.K. have "made a critical discovery about the way the most deadly species of malaria parasite invades human red blood cells," Reuters reports.

11 Nov 2011

New unsuspected role for nuclear receptor corepressor protein

By knocking out a key regulatory protein, scientists at the University of California, San Diego School of Medicine and the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland dramatically boosted insulin sensitivity in lab mice, an achievement that opens a new door for drug development and the treatment of diabetes.

11 Nov 2011

Universally effective malaria vaccine on the horizon

Scientists are excited with a new breakthrough in development of an effective vaccine against malaria. The latest study finds how malaria acts and how the vaccine would be able to protect individuals from malaria.

10 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

Receptor News and Research

Are genes and hormones determinants of empathy and sensitivity in human nature?

Researchers discover a factor in synapse-building and pruning

Male breast cancer patients report tamoxifen side effects

Just 20 seconds to know whether a stranger is trustworthy, kind or compassionate

Amgen receives EC approval to extend therapeutic indications for Vectibix

International consortium develops first-in-class adiponectin receptor agonist

New computer chip models how neurons communicate with each other at synapses

Specific gene variant may increase risk of premature death in people with alcohol dependency

Eliminating drug co-pays improves medication adherence in heart attack patients

Cortex third quarter net loss increases to $1,175,000

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Scientists suppress NCoR1 protein and create mighty mice

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

New unsuspected role for nuclear receptor corepressor protein

Universally effective malaria vaccine on the horizon

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

New genetic approach to treat fibrodysplasia ossificans progressiva

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News